Land: Deutschland
Sprache: Deutsch
Quelle: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
Antigene des Influenza-Virus A/New Caledonia/20/99 (H1N1), Stamm A/New Caledonia/20/99 IVR-116, Antigene des Influenza-Virus A/California/7/2004 (H3N2), Stamm NYMC X-157, Antigene des Influenza-Virus B/Shanghai/361/2002, Stamm B/Jiangsu/10/2003
Mylan Healthcare GmbH
Antigens of the Influenza Virus A/New Caledonia/20/99 (H1N1), strain A/New Caledonia/20/99 IVR-116, antigens of Influenza Virus A/California/7/2004 (H3N2), strain NYMC X-157, antigens of Influenza Virus B/Shanghai/361/2002, strain B/Jiangsu/10/2003
Suspension zur Injektion
Antigene des Influenza-Virus A/New Caledonia/20/99 (H1N1), Stamm A/New Caledonia/20/99 IVR-116 >= 15.µgHA; Antigene des Influenza-Virus A/California/7/2004 (H3N2), Stamm NYMC X-157 >= 15.µgHA; Antigene des Influenza-Virus B/Shanghai/361/2002, Stamm B/Jiangsu/10/2003 >= 15.µgHA
gültig